Prescribed Short-Acting Hormonal Contraceptive Use Among Premenopausal Females

What were the patterns and trends in prescribed short-acting hormonal contraceptive use among US premenopausal females from 1999 through March 2020, before the COVID-19 pandemic?In this serial cross-sectional study of 15 531 of premenopausal females, between the 1999 to 2000 and 2017 to 2020 survey cycles, the prevalence of prescribed short-acting hormonal contraceptive use increased among those aged 15 to younger than 20 years but did not change among females aged 20 to younger than 40 years, while use remained lower among non-Hispanic Black and Hispanic females compared with non-Hispanic White females across survey cycles.Differences in prescribed short-acting hormonal contraceptive use across age and racial and ethnic groups suggest that hormonal contraceptive use patterns in the US are shaped by more than individual preference alone and likely reflect evolving clinical practice, counseling, social context, and patterns of reproductive health care use over time.

Corresponding Authors: Adetunji T. Toriola, MD, PhD, MPH, Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, 660 S Euclid Ave, Campus Box 8100, St Louis, MO 63110 (a.toriola@wustl.edu); Lin Yang, PhD, Department of Cancer Epidemiology and Prevention Research, Cancer Care Alberta, Arthur Child Cancer Centre, 7th Floor, Office YC071433, 3395 Hospital Dr NW, Calgary, AB T2N 5G2, Canada (lin.yang@cancercarealberta.ca).

Link to the article in your story

We encourage you to link out to this article in your your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.